FDA accepts Northfield's BLA for red blood cell substitute PolyHeme
This article was originally published in Scrip
Executive Summary
The US FDAhas accepted Northfield Laboratories' BLA for its only product, a human haemoglobin-based red blood cell substitute named PolyHeme, for the treatment of urgent, large volume blood loss when a blood transfusion is required and red blood cells are not available.